• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Linden Capital Partners Acquires Alcresta Therapeutics, Inc.

    PR NEWSWIRE

    Alcresta Announces Move to New Corporate Headquarters in Waltham, MA

    PRNEWSWIRE

    Alcresta Therapeutics Announces Appointment of Chris Parrish as COO

    PRNEWSWIRE

    Data from the ASSURE Study of Long-Term Use of RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE Published in Journal of Pediatric Gastroenterology and Nutrition

    PRESS RELEASE

    Alcresta Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE Issued (Q9994) by CMS

    BIOSPACE

    Alcresta Presented Results at the North American Cystic F Conference-RELiZORB®

    BUSINESSWIRE

    Alcresta Receives New Innovative Technology Contract from Vizient, For RELiZORB®

    BUSINESSWIRE

    Alcresta Announces Positive Results, RELiZORB® Increased Fat Absorption

    BUSINESSWIRE

    Alcresta Therapeutics Receives 510(k) Clearance For Use of RELiZORB® in Children

    BUSINESSWIRE

    Alcresta Therapeutics Inc.say raised about $10 million in equity financing

    BIZJOURNALS

    Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics

    PRESS RELEASE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.